Within a certain price range free samples are available
Customized
Product Description
Product Description Paxista is an investigational antiviral therapy medicine with active ingredients Nirmatrelvir 150 MG and Ritonavir 100 MG approved for emergency use. The drug is indicated for treating mild-to-moderate coronavirus disease in adults and pediatric patients (aged 12 years and weight 40 kg) testing positive for SARS-CoV-2 virus, at high risk of progression, including hospitalization or death. Ritonavir is co-administered with Nirmatrelvir as it acts as a pharmacokinetic enhancer resulting in higher systemic concentrations and a longer half-life of Nirmatrelvir, thereby supporting a twice-daily administration regimen.